Jyong Biotech (MENS) Competitors $54.46 -1.24 (-2.23%) As of 10:57 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock MENS vs. SMMT, ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, and VRNAShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna QIAGEN Elanco Animal Health Verona Pharma PLC American Depositary Share Jyong Biotech (NASDAQ:MENS) and Summit Therapeutics (NASDAQ:SMMT) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Does the media prefer MENS or SMMT? In the previous week, Summit Therapeutics had 4 more articles in the media than Jyong Biotech. MarketBeat recorded 8 mentions for Summit Therapeutics and 4 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.73 beat Summit Therapeutics' score of 0.67 indicating that Jyong Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer MENS or SMMT? Summit Therapeutics has a consensus price target of $31.29, suggesting a potential upside of 42.32%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Summit Therapeutics 5 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.44 Is MENS or SMMT more profitable? Jyong Biotech's return on equity of 0.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Summit Therapeutics N/A -208.64%-181.28% Do institutionals & insiders hold more shares of MENS or SMMT? 4.6% of Summit Therapeutics shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, MENS or SMMT? Jyong Biotech has higher earnings, but lower revenue than Summit Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/ASummit Therapeutics$700K23,328.67-$221.32M-$1.01-21.77 SummarySummit Therapeutics beats Jyong Biotech on 8 of the 11 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$4.14B$1.01B$2.49B$10.43BDividend YieldN/A4.84%2.52%4.82%P/E RatioN/A1.2826.1626.98Price / SalesN/A30.03125.99130.89Price / CashN/A17.6445.0330.18Price / BookN/A7.6336.746.67Net IncomeN/A-$7.59M$6.97M$276.55M7 Day Performance-1.18%9.48%-1.50%-0.42%1 Month Performance-11.45%19.71%0.24%6.58%1 Year PerformanceN/A-11.74%58.95%40.76% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$54.46-2.2%N/AN/A$4.14BN/A0.0031Gap DownSMMTSummit Therapeutics2.7773 of 5 stars$22.93+7.4%$31.29+36.4%+14.9%$15.86B$700K-22.70110Gap DownASNDAscendis Pharma A/S3.1378 of 5 stars$208.43-0.5%$248.29+19.1%+61.7%$12.93B$393.54M-40.391,017News CoverageAnalyst ForecastGap UpRDYDr. Reddy's Laboratories2.6723 of 5 stars$14.36+0.1%$16.95+18.1%-8.3%$11.97B$3.81B21.7527,811Positive NewsVTRSViatris1.7256 of 5 stars$9.86+1.2%$10.40+5.5%-13.4%$11.36B$14.74B-3.4032,000ROIVRoivant Sciences3.3624 of 5 stars$16.21+1.1%$19.94+23.0%+36.2%$10.95B$29.05M-23.16860BBIOBridgeBio Pharma4.1457 of 5 stars$55.96+0.8%$63.94+14.3%+116.1%$10.61B$221.90M-13.68400MRNAModerna4.2452 of 5 stars$26.74-0.3%$41.81+56.4%-54.1%$10.48B$3.24B-3.555,800QGENQIAGEN4.3829 of 5 stars$47.30+1.0%$49.40+4.4%+10.8%$10.41B$1.98B27.955,765Analyst DowngradeELANElanco Animal Health2.6003 of 5 stars$20.04+1.4%$19.14-4.5%+39.5%$9.82B$4.44B23.309,000VRNAVerona Pharma PLC American Depositary Share1.4285 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive News Related Companies and Tools Related Companies SMMT Alternatives ASND Alternatives RDY Alternatives VTRS Alternatives ROIV Alternatives BBIO Alternatives MRNA Alternatives QGEN Alternatives ELAN Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
